Dose-related Decrease of Serum Coenzyme Q10 During Treatment With HMG-CoA Reductase Inhibitors

Mol Aspects Med. 1997;18 Suppl:S137-44. doi: 10.1016/s0098-2997(97)00014-9.

Abstract

Coenzyme Q10 (ubiquinone) the essential mitochondrial redox-component and endogenous antioxidant, packaged into the LDL + VLDL fractions of cholesterol, has been suggested as an important anti-risk factor for the development of atherosclerosis as explained by the oxidative theory. Forty-five hypercholesterolemic patients were randomized in a double-blind trial in order to be treated with increasing dosages of either lovastatin (20-80 mg/day) or pravastatin (10-40 mg/day) over a period of 18 weeks. Serum levels of coenzyme Q10 were measured parallel to the levels of cholesterol at baseline on placebo and diet and during active treatment. A dose-related significant decline of the total serum level of coenzyme Q10 was found in the pravastatin group from 1.27 +/- 0.34 at baseline to 1.02 +/- 0.31 mmol/l at the end of the study period (mean +/- S.D.), P < 0.01. After lovastatin therapy the decrease was significant as well and more pronounced, from 1.18 +/- 0.36 to 0.84 +/- 0.17 mmol/l, P < 0.001. Although HMG-CoA reductase inhibitors are safe and effective within a limited time horizon, continued vigilance of a possible adverse consequence from coenzyme Q10 lowering seems important during long-term therapy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antioxidants / analysis*
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / chemistry
  • Cholesterol, VLDL / blood
  • Coenzymes
  • Coronary Disease / blood
  • Coronary Disease / epidemiology
  • Double-Blind Method
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Lovastatin / adverse effects*
  • Lovastatin / pharmacology
  • Lovastatin / therapeutic use
  • Male
  • Middle Aged
  • Oxidation-Reduction
  • Pravastatin / adverse effects*
  • Pravastatin / pharmacology
  • Pravastatin / therapeutic use
  • Risk Factors
  • Ubiquinone / analogs & derivatives*
  • Ubiquinone / blood

Substances

  • Antioxidants
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • Coenzymes
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Ubiquinone
  • Cholesterol
  • Lovastatin
  • coenzyme Q10
  • Pravastatin